MannKind Corporation (NASDAQ:MNKD) will present at Goldman Sachs 35th Annual Global Healthcare Conference on June 12, 2014 at 11:20 am (PT) at the Terranea Resortin Rancho Palos Verdes, California. MannKind Corporation (NASDAQ:MNKD) weekly performance is 18.88%. On last trading day company shares ended up $9.51. Analysts mean target price for the company is $8.58. MannKind Corporation (NASDAQ:MNKD) distance from 50-day simple moving average (SMA50) is 44.12%.
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced on 27 May that it has dosed the first patient with BMN 701 (GILT-tagged Recombinant Human GAA) in the Phase 3 INSPIRE trial for Pompe disease. BMN 701 is a novel fusion protein of insulin-like growth factor 2 and acid alpha glucosidase (IGF2-GAA), designed to target delivery to the lysosomes where the enzyme is most needed. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) shares advanced 6.17% in last trading session and ended the day on $61.58. BMRN gross Margin is 82.90% and its return on assets is -8.90%.BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) quarterly performance is -23.81%.
Biopharmaceutical company Arrowhead Research Corp (NASDAQ:ARWR) developing targeted RNAi therapeutics announced that Christopher Anzalone, Ph.D., President and Chief Executive Officer, will present at the Jefferies 2014 Global Healthcare Conference on Thursday, June 5, 2014 at 9:30 a.m. EDT in New York City. Arrowhead Research Corp (NASDAQ:ARWR) shares moved up 7.33% in last trading session and was closed at $12.88, while trading in range of $11.85 – $12.93. Arrowhead Research Corp (NASDAQ:ARWR) year to date (YTD) performance is 18.71%.
Northwest Biotherapeutics Inc. (NASDAQ:NWBO) posted its quarterly earnings results on 21 may, Wednesday. The company reported ($0.46) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.33) by $0.13, Analyst Ratings Network.com reports. Northwest Biotherapeutics, Inc. (NASDAQ:NWBO) ended the last trading day at $5.90. Company weekly volatility is calculated as 7.79% and price to cash ratio as 18.24.Northwest Biotherapeutics, Inc. (NASDAQ:NWBO) showed a negative weekly performance of -9.65%.
Akebia Therapeutics Inc. (NASDAQ:AKBA) on 12 may reported a net loss of $9.7 million for the first quarter of 2014, compared to a net loss of $0.6 million for the first quarter of 2013. Net loss applicable to common stockholders, which includes accretion on preferred stock of $86.9 million, was $96.6 million for the first quarter of 2014, or ($43.37) per share. Akebia Therapeutics Inc. (NASDAQ:AKBA) weekly performance is 14.99%. On last trading day company shares ended up $26.31. Analysts mean target price for the company is $50.67. Akebia Therapeutics Inc. (NASDAQ:AKBA) distance from 50-day simple moving average (SMA50) is 19.04%.